Does cyproheptadine cause QT interval prolongation?

Cyproheptadine and QT Prolongation

Cyproheptadine does not cause clinically significant QT interval prolongation at therapeutic doses and is not classified as a QT-prolonging medication in major cardiovascular guidelines.

Evidence from Guidelines and Drug Labels

• The 2023 Canadian Cardiovascular Society guideline on prolonged QT intervals does not list cyproheptadine among QT-prolonging medications, despite comprehensive cataloging of antibiotics, antipsychotics, antidepressants, antiemetics, and other drug classes known to affect cardiac repolarization. 1

• The FDA-approved drug label for cyproheptadine lists cardiovascular disease as a precaution due to its atropine-like (anticholinergic) effects, but does not mention QT prolongation or torsades de pointes risk as adverse effects or warnings. 2

• Cyproheptadine is recommended as a treatment agent for serotonin syndrome, a condition where QT-prolonging medications must be avoided; this therapeutic use would be contraindicated if cyproheptadine itself prolonged the QT interval. 3

Supporting Research Evidence

• A 2014 animal study in halothane-anesthetized guinea pigs demonstrated that therapeutic to supra-therapeutic doses of cyproheptadine (0.1 and 1 mg/kg IV) "hardly affected the indices of ventricular repolarization," whereas the comparator antihistamine hydroxyzine significantly prolonged QT intervals at equivalent doses. 4

• The same study concluded that "cyproheptadine may be categorized into antihistamines with little effect on the ventricular repolarization," distinguishing it from other antihistamines known to block the hERG potassium channel. 4

Clinical Context: Antihistamines and QT Risk

• Among antihistamines, diphenhydramine is not classified as high-risk for QT prolongation by the 2023 Canadian Cardiovascular Society or 2010 AHA/ACC guidelines, and cyproheptadine carries even less cardiac risk than diphenhydramine based on available evidence. 5

• The 2014 European Heart Journal guideline on psychotropic medication risks discusses multiple drug classes but does not identify cyproheptadine as a QT-prolonging agent, despite reviewing antihistamines with anticholinergic properties. 6

Practical Recommendations

• Baseline ECG monitoring is not required when prescribing cyproheptadine at standard doses (12–24 mg/day for adults; 0.25 mg/kg/day for children) in patients without additional cardiac risk factors. 3, 2

• Cyproheptadine may be used safely in patients with baseline QT prolongation when indicated for serotonin syndrome, as it is the preferred serotonin antagonist and does not further prolong repolarization. 3

• The primary cardiovascular precautions for cyproheptadine relate to its anticholinergic effects (tachycardia, hypertension) rather than QT prolongation, particularly in patients with pre-existing cardiovascular disease or hypertension. 2

Key Clinical Pitfall to Avoid

• Do not confuse cyproheptadine with other antihistamines that do prolong the QT interval; cyproheptadine's anticholinergic side effects (dry mouth, urinary retention, tachycardia) are distinct from hERG channel blockade and do not increase torsades de pointes risk. 2, 4